Internal ribosome entry site (ires), vector containing same and uses thereof
CA 2357709 A1 · Owner: Beyaert, Rudi · Inventors: Cornelis, Sigrid; Beyaert, Rudi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The current invention relates to two isoforms p110 and p58 of PITSLRE protein , kinase which can be translated from the same p110 (.alpha.2-2) mRNA by an internal ribosome entry process. This means that p110 and p58 two proteins , with putative different functions are translated from a single mRNA species by using two AUGs within the same reading frame. These two proteins share the 439 C-terminal amino acids that contain the kinase domain. The IRES in the polycistronic p110 mRNA is the first IRES completely localized in the coding region of a cellular mRNA. Moreover, it was unexpectedly found that the IRES element is cell cycle regulated. Translation of p58 occurs in the G2/M stage …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 26, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 26, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 26, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.